[[1] Khamashta MA, Amigo MC. Antiphospholipid syndorme: overview of pathogenesis, diagnosis, and management. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME,Weisman MH, editors. Rheumatology, 6. Vol. 2. Philadelphia: Elsevier; 2015. p. 1144–52.]Search in Google Scholar
[[2] Ruiz-Irastorza G, CrowtherM, BranchW, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498–509.10.1016/S0140-6736(10)60709-X]Search in Google Scholar
[[3] Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, follow up study. Arthritis Rheum 2005;53:460–7.10.1002/art.21162]Search in Google Scholar
[[4] Gabrielli F, Alcini E, di Prima MA, Mazzacurati G, Masala C. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol 1995;51:117–26.10.1016/0167-5273(95)02357-3]Search in Google Scholar
[[5] Borowski A, Ghodsizad A, Cohnen M, Gams E. Recurrent embolism in the course of marantic endocarditis. Ann Thorac Surg 2005;79:2145–7.10.1016/j.athoracsur.2003.12.024]Search in Google Scholar
[[6] Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985–2000. Mayo Clin Proc 2001;76:1204–12.10.4065/76.12.1204]Search in Google Scholar
[[7] Moyssakis I, Tzioufas A, Triposkiadis F, Strateges N, Kyriakidis M. Severe aortic stenosis and mitral regurgitation in a woman with systemic lupus erythematosus. Clin Cardiol 2002;4:194–6.10.1002/clc.4960250412]Search in Google Scholar
[[8] Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep 2008;10:67–73.10.1007/s11926-008-0012-y]Search in Google Scholar
[[9] Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015;14:214–22.10.1016/j.autrev.2014.11.003]Search in Google Scholar
[[10] Jouhikainen T, Pohjola-Sintonen S, Stephansson E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 1994;3:167–72.10.1177/096120339400300307]Search in Google Scholar
[[11] Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89:411–9.10.1016/0002-9343(90)90368-N]Search in Google Scholar
[[12] Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T, Cruz-Cruz F, Romero-Cárdenas A, Keirns C, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999;137:973–8.10.1016/S0002-8703(99)70424-2]Search in Google Scholar
[[13] Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579–87.10.1161/01.CIR.93.8.1579]Search in Google Scholar
[[14] Morelli S, Bernardo ML, Viganego F, Sgreccia A, De Marzio P, Conti F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus 2003;12:805–12.10.1191/0961203303lu468oa]Search in Google Scholar
[[15] Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996;335:1424–30.10.1056/NEJM199611073351903]Search in Google Scholar
[[16] Turiel M, Sarzi-Puttini P, Peretti R, Bonizzato S, Muzzupappa S, Atzeni F, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005;96:574–9.10.1016/j.amjcard.2005.04.022]Search in Google Scholar
[[17] Dentali F, Manfredi E, Crowther M, Ageno W. Longduration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005;3:2121–3.10.1111/j.1538-7836.2005.01516.x]Search in Google Scholar
[[18] Sciascia S, Khamashta MA, D’Cruz DP. Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 2014;26:269–75.10.1097/BOR.0000000000000051]Search in Google Scholar
[[19] Bakshi J, Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus 2013;22:865–7.10.1177/0961203313491023]Search in Google Scholar
[[20] Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep 2016;18:74.10.1007/s11926-016-0623-7]Search in Google Scholar
[[21] Cohen H, Hunt BJ, Efthymiou M, Arachchillage DJ, Mackie IJ, Clawson S, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomized, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3:426–36.10.1016/S2352-3026(16)30079-5]Search in Google Scholar
[[22] Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27–35.10.1016/S0049-0172(97)80034-0]Search in Google Scholar
[[23] Erdozain JG, Ruiz-Irastorza G, Segura MI, Amigo MC, Espinosa G, Pomar JL, et al. Cardiac Valve Replacement in Patients with Antiphospholipid Syndrome. Arthritis Care Res (Hoboken) 2012;64:1256–60.10.1002/acr.2167022422594]Search in Google Scholar
[[24] Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg 2008;33:168–81.10.1016/j.ejcts.2007.11.00418082413]Search in Google Scholar